NCT02057835View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Healthy
Interventions
DRUG

Placebo to BI 691751

Placebo to BI 691751

DRUG

BI 691751 high dose

BI 691751 high dose

DRUG

BI 691751 middle dose

BI 691751 middle dose

DRUG

Placebo to BI 691751

Placebo to BI 691751

DRUG

BI 691751 low dose 1

BI 691751 low dose 1

DRUG

Placebo to BI 691751

Placebo to BI 691751

DRUG

Placebo to BI 691751

Placebo to BI 691751

DRUG

BI 691751 low dose 2

BI 691751 low dose 2

Trial Locations (1)

Unknown

1334.5.82001 Boehringer Ingelheim Investigational Site, Seoul

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY